Twenty-three years’ experience in Cell and Gene Therapy (CGT) and the technology involved in the processing and manufacturing. 

Eighteen years at Miltenyi Biotec, initially running their bone marrow transplant and cell therapy business, technically and commercially.  Looking back, this means playing a very small part in progressing products and processes in the clinic that have now had companies grow up around them, such as Autolus, Adaptimmune, Orchard, Quell, Resolution and more. 

Going on to run Miltenyi’s strategic partnerships with such partners as Autolus and GSK.  Central to the Prodigy launch and Miltenyi’s widening cell therapy and analytics portfolios and placing them in the industry, actually selling and placing the first Prodigys in the field and part of the first clinical use of the Prodigy for CAR T manufacturing, thus leading Miltenyi’s way into acadaemia, the clinic and bioindustry.

Then a fresh change to gain deep experience as a founding member of Ori Biotech (and first employee) as their Chief Business Officer, developing a purpose-built manufacturing cell processing technology more amenable to scale.  Experience in building a technology, building a company, building partnerships and collaborations and supporting investor interest and a total of $150M raised. 
 

A long road in cell and gene therapy manufacturing that now seems always to have been leading to Cellular Origins.  As Head of Global Business Development and Marketing at Cellular Origins, personal passions and vision are aligned in making a difference and making the evolutionary step in manufacturing technology to where it needs to be.  To put real substance and realisation to the word that is too often said but seldom meant, ‘Automation’, is now ‘Full Automation’, bringing robotics to our maturing industry.  Developing and maintaining current partnerships, discovering and securing new partnerships and progressing key industry collaborations with other technology providers, as manufacturing advanced therapies at scale is a challenge that can only be surmounted with in partnership.  To best place Cellular Origins to disrupt and evolve CGT manufacturing and to bridge the gap between the need and the ability to scale and to make a positive difference to the lives of as many patients as can benefit from the promise of CGT.